These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 23552436)

  • 1. Algorithm for identifying chemotherapy/biological regimens for metastatic colon cancer in SEER-Medicare.
    Bikov KA; Mullins CD; Seal B; Onukwugha E; Hanna N
    Med Care; 2015 Aug; 53(8):e58-64. PubMed ID: 23552436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and demographic characteristics associated with the receipt of chemotherapy treatment among 7951 elderly metastatic colon cancer patients.
    Reese ES; Onukwugha E; Hanna N; Seal BS; Mullins CD
    Cancer Med; 2013 Dec; 2(6):907-15. PubMed ID: 24403264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the type of first-line regimens influence the receipt of second-line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patients.
    Zheng Z; Hanna N; Onukwugha E; Reese ES; Seal B; Mullins CD
    Cancer Med; 2014 Feb; 3(1):124-33. PubMed ID: 24403130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of second-line chemotherapy/biologics among elderly metastatic colon cancer patients.
    Zheng Z; Onukwugha E; Hanna N; Bikov K; Seal B; Mullins CD
    Adv Ther; 2014 Jul; 31(7):724-34. PubMed ID: 25022528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in the Treatment of Metastatic Colon and Rectal Cancer in Elderly Patients.
    Bradley CJ; Yabroff KR; Warren JL; Zeruto C; Chawla N; Lamont EB
    Med Care; 2016 May; 54(5):490-7. PubMed ID: 26900834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of Biologics Use Across Treatment Lines in Elderly (Age >65) Medicare Patients With Metastatic Colon Cancer.
    Bikov KA; Mullins CD; Hung A; Seal B; Onukwugha E; Hanna N
    Oncologist; 2016 Jun; 21(6):676-83. PubMed ID: 27125751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Bevacizumab for Elderly Patients With Stage IV Colon Cancer: Analysis of SEER-Medicare Data.
    Raab GT; Lin A; Hillyer GC; Keller D; O'Neil DS; Accordino MK; Buono DL; Hur C; Kiran RP; Wright JD; Hershman DL; Neugut AI
    Clin Colorectal Cancer; 2019 Sep; 18(3):e294-e299. PubMed ID: 31266707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer.
    Panchal JM; Lairson DR; Chan W; Du XL
    Clin Colorectal Cancer; 2013 Jun; 12(2):113-21. PubMed ID: 23137529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma.
    Aly A; Johnson C; Yang S; Botteman MF; Rao S; Hussain A
    J Med Econ; 2019 Jul; 22(7):662-670. PubMed ID: 30836812
    [No Abstract]   [Full Text] [Related]  

  • 10. FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data.
    Neugut AI; Lin A; Raab GT; Hillyer GC; Keller D; O'Neil DS; Accordino MK; Kiran RP; Wright J; Hershman DL
    Clin Colorectal Cancer; 2019 Jun; 18(2):133-140. PubMed ID: 30878317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer.
    Schrag D; Rifas-Shiman S; Saltz L; Bach PB; Begg CB
    J Clin Oncol; 2002 Oct; 20(19):3999-4005. PubMed ID: 12351597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
    Schwartz KL; Simon MS; Bylsma LC; Ruterbusch JJ; Beebe-Dimmer JL; Schultz NM; Flanders SC; Barlev A; Fryzek JP; Quek RGW
    Cancer; 2018 May; 124(10):2104-2114. PubMed ID: 29505670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: Completion of therapy by Medicare patients with stage III colon cancer.
    Gibbs P; McLaughlin S; Skinner I; Jones I; Hayes I; Chapman M; Johns J; Lim L; Faragher I
    J Natl Cancer Inst; 2006 Nov; 98(21):1582. PubMed ID: 17077360
    [No Abstract]   [Full Text] [Related]  

  • 14. Factors Associated with Adherence Rates for Oral and Intravenous Anticancer Therapy in Commercially Insured Patients with Metastatic Colon Cancer.
    Seal BS; Anderson S; Shermock KM
    J Manag Care Spec Pharm; 2016 Mar; 22(3):227-35. PubMed ID: 27003552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of various prognostic nodal factors, adjuvant chemotherapy and survival among stage III colon cancer patients over 65 years: an analysis using surveillance, epidemiology and end results (SEER)-Medicare data.
    Hanna NN; Onukwugha E; Choti MA; Davidoff AJ; Zuckerman IH; Hsu VD; Mullins CD
    Colorectal Dis; 2012 Jan; 14(1):48-55. PubMed ID: 21689262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of irinotecan-based chemotherapy regimens in elderly Medicare patients with metastatic colorectal cancer.
    Obeidat NA; Pradel FG; Zuckerman IH; DeLisle S; Mullins CD
    Am J Geriatr Pharmacother; 2009 Dec; 7(6):343-54. PubMed ID: 20129255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front-line regimens using the SEER-Medicare data.
    Goto D; Khairnar R; Yared JA; Yong C; Romanus D; Onukwugha E; Slejko JF
    Cancer Med; 2020 Jan; 9(2):626-639. PubMed ID: 31801177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer.
    Zuckerman IH; Rapp T; Onukwugha E; Davidoff A; Choti MA; Gardner J; Seal B; Mullins CD
    J Am Geriatr Soc; 2009 Aug; 57(8):1403-10. PubMed ID: 19563521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly.
    Neugut AI; Matasar M; Wang X; McBride R; Jacobson JS; Tsai WY; Grann VR; Hershman DL
    J Clin Oncol; 2006 May; 24(15):2368-75. PubMed ID: 16618946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of race/ethnicity and socioeconomic status on adjuvant chemotherapy use among elderly patients with stage III colon cancer.
    Hsieh MC; Chiu YW; Velasco C; Wu XC; O'Flarity MB; Chen VW
    J Registry Manag; 2013; 40(4):180-7. PubMed ID: 24625772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.